Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study

被引：0
|
作者：
von Amsberg, G. [1 ]
Powles, T. [2 ]
Loriot, Y. [3 ]
Ravaud, A. [4 ]
Vogelzang, N. J. [5 ]
Duran, I. [6 ]
Retz, M. [7 ]
De Giorgi, U. [8 ]
Oudard, S. [9 ]
Bamias, A. [10 ]
Koeppen, H. [11 ]
Leng, N. [11 ]
Kadel, E. E. [11 ]
Hegde, P. S. [11 ]
Cui, N. [11 ]
Shen, X. [11 ]
Green, M. [11 ]
Banchereau, R. [11 ]
Mariathasan, S. [11 ]
van der Heijden, M. S. [12 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Ctr Oncol, Hamburg, Germany
[2] Queen Mary Univ London, Barts Canc Inst, London, England
[3] Gustave Roussy, Villejuif, France
[4] Hop St Andre CHU, Bordeaux, France
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] Univ Seville, Inst Biomed Sevilla, Hosp Univ Virgen del Rocio, CSIC, Seville, Spain
[7] Tech Univ Munich, Munich, Germany
[8] IRST IRCCS, Meldola, Italy
[9] Hop Europeen Georges Pompidou, Paris, France
[10] Univ Athens, ALEXANDRA Hosp, Athens, Greece
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P990
引用
收藏
页码：325 / 326
页数：2
相关论文
共 42 条
  • [21] IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
    Galsky, Matt D.
    Grande, Enrique
    Davis, Ian D.
    De Santis, Maria
    Arija, Jose Angel Arranz
    Kikuchi, Eiji
    Mecke, Almut
    Thastrom, Ann Christine
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211
    Fallara, Giuseppe
    Belladelli, Federico
    Robesti, Daniele
    Malavaud, Bernard
    Tholomier, Come
    Mokkapati, Sharada
    Montorsi, Francesco
    Dinney, Colin P.
    Msaouel, Pavlos
    Martini, Alberto
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03) : 188e9 - 188e17
  • [23] Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.
    Galsky, Matt D.
    Bamias, Aristotelis
    Arranz Arija, Jose Angel
    Davis, Ian D.
    De Santis, Maria
    Kikuchi, Eiji
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li Jian-Ri
    Mecke, Almut
    Mariathasan, Sanjeev
    Banchereau, Romain
    Huang Xinhui
    Lee, Chooi Peng
    Grande, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [24] Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
    Bamias, A.
    De Santis, M.
    Arranz, J. A.
    Grande, E.
    Galsky, M. D.
    Kikuchi, E.
    Park, S. H.
    De Giorgi, U.
    Garcia del Muro, X.
    Mencinger, M.
    Alekseev, B.
    Puente, J.
    Izumi, K.
    Gumus, M.
    Mellado Gonzalez, B.
    Li, J-R.
    Quach, C.
    Ding, B.
    Bernhard, S.
    Davis, I. D.
    ANNALS OF ONCOLOGY, 2020, 31 : S551 - S552
  • [25] Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
    Rosenberg, J.
    Petrylak, D.
    Abidoye, O.
    Van der Heijden, M. S.
    Hofman-Censits, J.
    Necchi, A.
    O'Donnell, P. H.
    Balmanoukian, A.
    Loriot, Y.
    Retz, M.
    Perez-Gracia, J. L.
    Dawson, N. A.
    Balar, A.
    Galsky, M. D.
    Fleming, M. T.
    Powles, T.
    Cui, N.
    Mariathasan, S.
    Fine, G. D.
    Dreicer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S720 - S720
  • [26] Atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130.
    Galsky, Matthew D.
    Arranz, Jose Angel
    Grande, Enrique
    De Santis, Maria
    Davis, Ian D.
    Kikuchi, Eiji
    Garcia del Muro, Xavier
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    O'Donnell, Peter H.
    Shen, Xiaodong
    Lee, Chooi
    Mecke, Almut
    Mariathasan, Sanjeev
    Bamias, Aristotelis
    CANCER RESEARCH, 2021, 81 (13)
  • [27] Phase III study of atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with treatment-naive advanced, recurrent or metastatic NSCLC unsuitable for platinum (plat)-based chemo
    Lee, S. M.
    Schulz, C.
    Cardona, A.
    Bartakova, P.
    Peters, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
    Pachynski, R.
    Chatta, G.
    Jain, R. K.
    Moon, H.
    Sweis, R.
    Delacroix, S.
    Fang, T.
    Fling, S. P.
    Lacroix, A.
    Kaiser, J.
    Sharon, E.
    Yu, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1204 - S1205
  • [29] Atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.
    Galsky, Matt D.
    Arija, Jose Angel Arranz
    De Santis, Maria
    Davis, Ian D.
    Bamias, Aristotelis
    Kikuchi, Eiji
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    O'Donnell, Peter H.
    Bernhard, Sandrine
    Lee, Chooi Peng
    Bene-Tchaleu, Fabiola
    Mariathasan, Sanjeev
    Grande, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [30] CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    Joseph, Richard W.
    Loriot, Yohann
    Luis Perez-Gracia, Jose
    Dreicer, Robert
    Petrylak, Daniel P.
    van der Heijden, Michiel S.
    Hoffman-Censits, Jean
    Shen, Xiadong
    Fear, Simon
    Pavlova, Julie
    Rosenberg, Jonathan E.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1039 - E1039
12345